Skip to main content
. 2023 Jul 31;120(32):e2309967120. doi: 10.1073/pnas.2309967120

Fig. 4.

Fig. 4.

Activin E signals via ACVR1C to suppress PPARG in adipose tissue. (A) Body weight increase in 7- to 11-wk-old male WT mice treated with control monoclonal antibody (mAb) or neutralizing ACVR1C mAb while on HFD (n = 8 to 9). (B–D) Fasted weights of epididymal (B) and subcutaneous (C) white adipose tissue and liver (D) (n = 8 to 9). (E) Plasma insulin levels before (baseline) and 2 or 4 wk after Control mAb or ACVR1C neutralizing mAb administration to WT mice (n = 8 to 9). (F) Insulin tolerance test in WT and Acvr1c−/− mice on high-fat diet (n = 10). (G to I) Fasted weights of epididymal (G) and subcutaneous (H) white adipose tissue and liver (I) 6 wk following Control AAV or Inhbe AAV administration to WT or Acvr1c−/− mice on chow diet (n = 11). (J and K) Epididymal WAT mRNA levels of activin target genes Pmepa1 and Serpine1 (J), and adipose transcription factor Pparg (K), relative to Control AAV in WT and Acvr1c−/− mice (n = 10 to 11). Mean ± SEM are shown in all graphs. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.